Physician profile
David A Ochoa
NPI 1922059385
$7,025.66
in general payments reported to CMS, 2019-2025
40 companies · $969 in 2025
The $969 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $1,419 · 2021: $1,166 · 2022: $822 · 2023: $760 · 2024: $816 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,308.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $917.65 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $911.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $537.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $395.76 | 2021-2025 | |
| Amarin Pharma, INC. | $323.53 | 2019-2022 | |
| Pfizer INC. | $284.88 | 2023-2025 | |
| Allergan, INC. | $232.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $216.23 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $207.14 | 2019-2024 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $163.04 | 2020-2025 | Nexletol |
| Abbott Laboratories | $160.83 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $128.99 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.69 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $101.72 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ochoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.